2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
22
Lung Neoplasms
9
Lymphoma, Large-Cell, Anaplastic
4
Carcinoma
4
Carcinoma, Squamous Cell
2
Carcinoma, Large Cell
2
Brain Neoplasms
2
Adenocarcinoma
2
ALK-positive Advanced NSCLC
2
Sexual Dysfunction, Physiological
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms
1
Neoplasm Metastasis
1
NSCLC
1
Meningioma
1
Granuloma, Plasma Cell
1
Gastrointestinal Neoplasms
1
Eunuchism
1
Erectile Dysfunction
1
Ependymoma
1
Disease Progression
1
Carcinoma, Pancreatic Ductal
1
Breast Neoplasms
1
ALK-positive NSCLC
1
ALK+ Advanced NSCLC
1
Interventions
brigatinib
1
alectinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
ALK+ Advanced NSCLC
×
brigatinib
×
Clear all
NCT03596866
2025-09-12
ALTA-3
Takeda
Phase 3
Completed
248 enrolled
20 charts